

systemic therapy alone will result in inferior results. Many investigators support the use of radiotherapy after the completion of chemotherapy. The recent and rapid development and application of the microarray technology for identification of patients at risk for relapse should also be focused on identifying those patients who have tumours tending to relapse only locally versus systemically aiming at tailoring the up-front therapy more optimally.

343

### Epidermal Growth Factor Receptor (EGFR) therapies in colorectal carcinoma - the European data

D. Cunningham, I. Chau. *The Royal Marsden Hospital, Department of Medicine, Sutton, United Kingdom*

EGFR is expressed or upregulated in 60-85% of CRC and its expression is associated with poor survival. The two most extensively evaluated therapeutic approaches targeting the EGFR signalling pathway are the use of monoclonal antibodies (mAb) and tyrosine kinase inhibitors (TKI). Cetuximab is a chimeric mAb that specifically binds to the EGFR. Two US phase II non-randomised studies, conducted in patients with advanced CRC refractory to irinotecan and fluorouracil based chemotherapy, have shown an objective response rate (ORR) of 22.5% when combined with the same dose and schedule of irinotecan and ORR of 10.5% when cetuximab was used as monotherapy. A large European multicentre randomised study was performed comparing combination of cetuximab and irinotecan with cetuximab monotherapy in the same patient population. 218 patients were randomised to the combination arm and 111 to the monotherapy arm. Baseline characteristics were balanced with 63% of patients had prior oxaliplatin exposure. The ORR was 22.9% (95% confidence interval [CI]: 17.5-29.1%) in the combination arm and 10.8% (95% CI 5.7-18.1%) in the monotherapy arm and this difference in ORR was significant ( $p=0.0074$ ). ORR in both arms were similar in those with prior oxaliplatin treatment and appeared to correlate with the occurrence of skin reaction, although no correlation was seen with the intensity of immunohistochemical EGFR staining on tumour samples. In addition, time to tumour progression was significantly longer in the combination arm compared to the monotherapy arm (median 4.1 months vs. 1.5 months respectively; log rank  $p$

344

### EGFR inhibitors in the treatment of lung cancer

G. Giaccone. *Vrije Universiteit Amsterdam, Department of Medical Oncology, Amsterdam, The Netherlands*

Epidermal Growth Factor Receptor (EGFR) is commonly overexpressed in a number of epithelial malignancies and is often associated with an aggressive phenotype (e.g. non-small cell lung cancer (NSCLC), bladder cancer). EGFR is present in over 50% of cases of NSCLC, head & neck squamous cell carcinomas (HNSCC) and colon cancer. Several EGFR-targeting agents have been recently developed (C225, ABX-EGF, E7.6.3, EMD 55900, ICR62, ZD1839, CP358774, PD168393, CGP75166/PK1166, CGP59326A, BIBX1382). The 2 most advanced EGFR inhibitors in development are C225 (CetuximabTM) and ZD1839 (IressaTM). C225 is an antibody directed against the ligand binding domain of human EGFR, which competes for receptor binding with EGF and other ligands. In vitro, CetuximabTM inhibits EGFR tyrosine kinase (TK) activity and proliferation of EGFR-overexpressing squamous cell carcinoma cell lines. Synergy was observed with doxorubicin, cisplatin and radiation in preclinical models. In phase I trials, major toxicity has been dermatological (rash and acneic skin reactions); allergic reactions have also been observed in about 3% of cases. This agent, administered iv. weekly, is presently in phase III trials in HNSCC and colon cancer. IressaTM, a synthetic molecule which targets the EGFR ATP binding site, is a very specific inhibitor of EGFR TK activity. Synergy has been observed with paclitaxel and cisplatin. In phase I trials, responses were seen in advanced NSCLC, and cutaneous toxicity and diarrhea were the most important side effects. Oral chronic administration daily is feasible. Two large randomized trials have been completed in advanced NSCLC in combination with chemotherapy. A large phase II study in second and third line has demonstrated a single agent activity of 18.5%. Another large phase II study in patients who received prior platinum and docetaxel obtained a response rate of 11%. There was no difference in response rate between the 250 and the 500 mg/day doses, but side effects were higher in patients who received the 500 mg dose. A very similar small molecule, OSI-774 (Tarceva), has also shown activity in this setting. Two large randomized phase III studies of Iressa have recently been completed and analyzed in which 2 doses of Iressa (250 or 500 mg/day) or

placebo were given in combination with 2 different chemotherapy regimens (carboplatin-paclitaxel or carboplatin-gemcitabine). These studies failed to demonstrate an increase in survival by adding Iressa together with chemotherapy in patients with advanced NSCLC.

345

### EGFR therapies with radiation (the head and neck data)

P. Harari. *University of Wisconsin, Dept of Human Oncology, Madison, USA*

Over one half of cancer patients worldwide receive radiation in the treatment of their cancer, and for several tumor types such as squamous cell cancer (SCC) of the head and neck (H&N), radiation represents a central or stand alone form of therapy. The rich overexpression of epidermal growth factor receptor (EGFR) in the vast majority of H&N cancer patients provides a particularly strong clinical/biological rationale for study of EGFR inhibitory strategies in this patient cohort. Substantial preclinical data identifies the capacity of EGFR inhibitory agents to augment the anti-tumor effects of ionizing radiation. Mechanisms for enhanced radiation response following EGFR inhibition include effects on cellular proliferation, apoptosis, damage repair, angiogenesis, invasion and metastases. Clinical trials which specifically evaluate the impact of EGFR inhibition on outcome for advanced H&N cancer patients are maturing. Several phase I/II clinical trials with anti-EGFR monoclonal antibodies and with small molecule inhibitors of the EGFR tyrosine kinase are underway or complete in H&N cancer patients in combination with radiation or with chemoradiation. In the Phase III setting, an international trial has recently completed enrollment of 416 patients treated definitively for advanced SCC of the H&N. Patients received either high-dose radiation alone (majority with hyperfractionation or concomitant boost radiation schedules) or radiation plus weekly infusions of the monoclonal antibody C225 (Erbix, Cetuximab) during a seven-week treatment course. This represents a very powerful clinical trial for the EGFR field in that it will provide an unencumbered assessment regarding the capacity of EGFR inhibition to modulate radiation response in a large cohort of advanced cancer patients treated with curative intent. Locoregional tumor control and overall survival will be analyzed in this randomized trial. Correlative studies will also be performed from tumor materials gathered from patients for EGFR analysis. In light of consistently high expression levels of EGFR, H&N cancer has also served as a valuable model for examining response rates for EGFR inhibitors in the recurrent and metastatic disease setting. The current status of EGFR inhibitor studies in H&N cancer will be updated during this session.

346

### EGFR therapies in other tumour types

J. Baselga. *Hospital Universitari Valle de Hebron, Department of Medical Oncology, Barcelona, Spain*

The EGFR is expressed in a variety of tumors including non-small cell lung cancer, colorectal cancer, head and neck tumor, renal cell carcinoma, ovarian, prostate and pancreatic tumors, among others. In addition of the antitumor activities reported with anti-EGFR compounds in non-small-cell-cancer and colon carcinomas, antitumor activity has also been reported in other tumor types. Studies with the monoclonal antibody (Mab) IMC-C225 (cetuximab) have been conducted. In patients with refractory head and neck cancer, with documented progression after having received at least two cycles of platinum-based therapy, an 11% response rate was observed when IMC-C225 was added to the platinum regimen. A small phase III study in head and neck tumors comparing cisplatin and placebo to cisplatin and IMC-C225, more than doubling of the response rate was observed in the IMC-C225 arm. IMC-C225 can also be administered safely in patients with head and neck cancer, when given in combination with radiation therapy, with 13 complete responses and 2 partial responses in 16 patients. A phase III study of radiation + IMC-C225 in patients with advanced head and neck tumors has completed accrual. In a phase II study of another anti-EGFR Mab, ABX-EGF, in advanced renal cell carcinoma, clinical activity was also documented in patients that had failed or were unable to receive IL-2. EMD-7200, a humanized Mab, has also shown activity against a variety of tumor types. There is also emerging data of clinical activity with low molecular weight erbB (EGFR and related receptor-family members) tyrosine kinase inhibitors (TKI). In a single agent phase II study with the anti-EGFR TKI ZD1839 in tumors of the head and neck, an 11% response rate was seen. No activity has been seen against prostate carcinoma and minimal activity against breast cancer. Studies with OSI-774, another EGFR inhibitor, have also reported activity in ovarian carcinoma, head neck tumors